T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.

<h4>Background</h4>Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2DLs) are highly expressed in glioblastomas and are considered promising t... View More